Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 30, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 330,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,507.06 pence per share.
- Treasury Shares Held: 157,194,678 shares following the transaction.
- Shares in Issue: 5,817,093,910 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 330,000 shares on March 30, 2006. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 330,000 shares purchased at 1,507.06 pence per share.
- Confirm the updated total number of shares in issue (5,817,093,910) and treasury holdings (157,194,678).
- Review the full Annual General Meeting minutes from May 25, 2005, to understand the scope of the share repurchase authority.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.